Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Laparoscopic Hepatectomy
Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Laparoscopic Hepatectomy--A Single-center, Randomized, Controlled Clinical Study
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Ping Chen, MD
- Telefonnummer: 13821017600
- E-Mail: sly178604@126.com
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Age between 18 and 75 years, any gender;
- American Society of Anesthesiologists (ASA) score of I or II;
- BMI between 18 kg/m² and 30 kg/m²;
- Patients scheduled for laparoscopic liver resection under general anesthesia, with surgery lasting less than 6 hours;
- Surgical incision less than 10 cm;
- Able to understand pain intensity assessment methods.
Participants understand the purpose and procedures of this study, voluntarily participate, and sign a written informed consent form.
Exclusion Criteria:
- Patients allergic to opioids, flurbiprofen ester, or any other ingredients in the investigational drugs.
- Patients expected to use continuous epidural analgesia or local block analgesia during the treatment period.
- Patients with a history of gastrointestinal ulcers or bleeding who need treatment.
- Patients undergoing emergency surgery or trauma.
- Patients whose surgery needs to be converted to open abdominal surgery.
- Patients unwilling to use patient-controlled intravenous analgesia (PCIA).
- Patients with a history of upper abdominal surgery.
- Patients expected to require postoperative continued intubation.
- Patients needing postoperative admission to the ICU.
- Patients with any of the following disease history or evidence before screening:
- Severe cardiovascular or pulmonary diseases (myocardial infarction, heart failure, or respiratory failure).
- Neurological or psychiatric history: brain injury, intracranial hypertension, schizophrenia, mania, etc., judged by the investigator as not suitable for the study.
- History of digestive diseases: intestinal obstruction or other digestive system diseases that may cause nausea or vomiting as judged by the investigator; accompanied by other severe digestive tract issues affecting digestion (e.g., severe constipation, duodenal stasis syndrome, etc.), or other digestive diseases evaluated by the investigator as unsuitable for the study.
- Patients with obvious chronic dizziness or diagnosed vestibular function disorders (other than motion sickness), including but not limited to peripheral vestibular syndrome or central vestibular syndrome.
- Patients who received neoadjuvant treatment before surgery.
- Patients who experienced nausea, retching, or vomiting within 24 hours before anesthesia induction (excluding bowel prep-related cases).
- Known allergy or contraindication to other anesthetics or antiemetics that may be used during the trial.
- Patients who used drugs with unclear half-lives that have analgesic or antiemetic effects within 14 days before randomization, or whose last use was less than 5 half-lives or the drug's effective duration (whichever is longer), including but not limited to opioids, non-opioid analgesics, antiemetics (or drugs with antiemetic effects), sedatives, anesthetics, corticosteroids, and other similar drugs.
- Patients needing dialysis or who have alcoholism during treatment.
- Pregnant or breastfeeding women, or those planning pregnancy during the study period or within 3 months after study completion.
- Subjects the investigator believes have any other factor making them unsuitable for this clinical study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Anruikefen
|
For patients undergoing laparoscopic liver resection, randomization is completed within 2 hours after surgery.
Within 30 minutes after successful randomization, they receive their first injection of either Anruikefen or Flurbiprofen Ester.
After the first dose, at 8±1h, 16±1h, 24±1h, 32±1h, 40±1h, 48±1h, 56±1h, and 64±1h, each participant is given a corresponding dose of Anruikefen IV infusion
|
|
Placebo-Komparator: Flurbiprofen Ester
|
For patients undergoing laparoscopic liver resection, randomization is completed within 2 hours after surgery.
Within 30 minutes after successful randomization, they receive their first injection of either Anruikefen or Flurbiprofen Ester.
After the first dose, at 8±1h, 16±1h, 24±1h, 32±1h, 40±1h, 48±1h, 56±1h, and 64±1h, each participant is given a corresponding dose of Flurbiprofen Ester IV infusion.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
1. Area under the NRS pain score curve 24 hours after medication (AUC-NRS24)
Zeitfenster: 24 hours after surgery
|
24 hours after surgery
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Pain intensity at rest and during movement (assess pain scores at 30 min, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 72 h after the first dose).
Zeitfenster: 0-72 hours after surgery
|
0-72 hours after surgery
|
|
Pain intensity difference (PID) at 30 min, 1, 3, 6, 12, 24, 48, and 72 h after dosing. Pain was assessed by NRS (0-10; 0=no pain, 10=severe pain). PID = baseline score (pre-dose/pre-op, 0 h) minus score at each time point. Unit: points.
Zeitfenster: 0-72 hours after surgery
|
0-72 hours after surgery
|
|
Sum of Pain Intensity Difference (SPID) at 30 min, 1, 3, 6, 12, 24, 48, and 72 h post-dose. NRS (0-10; 0=no pain, 10=worst pain) assessed pain. TPID = baseline score (pre-dose, 0 h) - score at each time point. Unit: points.
Zeitfenster: 0-72 hours after surgery
|
0-72 hours after surgery
|
|
Total Sufentanil dose administered via PCIA pump within 24 hours post-surgery. Measurement tool: PCIA pump (or electronic medical record). Measurement unit: micrograms (μg).
Zeitfenster: 24 hours after surgery
|
24 hours after surgery
|
|
Baseline, then assess NRS scores (visceral pain, incision pain, shoulder pain) at 30 min, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 72 h after the first dose.
Zeitfenster: 0-72 hours after surgery
|
0-72 hours after surgery
|
|
Use of rescue pain medication: cumulative usage of rescue pain medication (morphine injection mg) at 072h after the first dose
Zeitfenster: 0-72 hours after surgery
|
0-72 hours after surgery
|
|
The proportion of patients needing rescue pain relief within 72 hours after the first dose and the total amount of rescue medication used
Zeitfenster: 0-72 hours after surgery
|
0-72 hours after surgery
|
|
Incidence of nausea, vomiting, and PONV within 72 hours after the first dose
Zeitfenster: 0-72 hours after surgery
|
0-72 hours after surgery
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Erkrankungen des Nervensystems
- Neurobehaviorale Manifestationen
- Wahrnehmungsstörungen
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Agnosie
- Organische Chemikalien
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Säuren, acyclisch
- Carboxylsäuren
- Kohlenwasserstoffe, aromatisch
- Benzolderivate
- Propionate
- Biphenylverbindungen
- Flurbiprofen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- E20261121
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .